Wir sind mit live!
Mehr erfahren
Lite Strategy Inc
LITS
LITS
Profil: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Mitarbeiter: 5
Nachrichten
Positiv
Neutral
Negativ
Stimmung
3 Monate
Positiv
0 %
Neutral
100 %
Negativ
0 %
Kursdiagramme mit Lightweight Charts™ umgesetzt